L
Laboratory for Advanced Medicine
Providing easy and affordable access to convenient tests to monitor health and allow peace of mind
About Laboratory for Advanced Medicine
Helio Genomics, formerly known as Helio Health, is a commercial-stage, AI-driven diagnostics company founded in 2016. The company's genesis traces back to research at the UC San Diego Genomic Institute, where scientists exploring methylation for aging discovered its potential for cancer detection. This led to a partnership and the spin-out of nine patent families, forming the foundation of the company. Co-founded by Justin Chen Li and Shu Li, the firm operates with a mission to make cancer screening simple, accessible, and accurate through a blood test. The business has established a multinational presence with headquarters in Irvine, California, facilities in Indiana, and collaborations in China.
Helio Genomics targets a significant unmet need in the oncology market, focusing initially on liver cancer, one of the most prevalent cancers worldwide and the fastest-growing cause of cancer deaths in the U.S. The company's business model revolves around the development and commercialization of its diagnostic tests for clients including physicians and high-risk patient groups. Its flagship product, HelioLiver, is a multi-analyte liquid biopsy test designed for the early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer. This test is available as a Laboratory Developed Test (LDT) in its CLIA-certified labs and is currently under review by the FDA for potential approval as a Class III medical device.
The core technology, the ECLIPSE™ platform, leverages artificial intelligence and machine learning to analyze proprietary DNA methylation signatures from cell-free DNA (cfDNA) in the blood. The HelioLiver test integrates this cfDNA methylation analysis with data from serum protein markers and patient demographic information. This multi-modal approach has demonstrated superior sensitivity in clinical trials compared to the standard of care, ultrasound, particularly in detecting small, early-stage tumors when treatment is most effective. By offering a simple blood draw, Helio addresses the low adherence rates and performance issues associated with routine ultrasound surveillance for at-risk populations, such as patients with cirrhosis or chronic hepatitis B.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Nov 2019 | $86M | $344M | Undisclosed | — |
Growth signals
Latest recorded traffic for Laboratory for Advanced Medicine is 230 monthly website visits. Laboratory for Advanced Medicine's team grew 4.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Laboratory for Advanced Medicine in the Irvine ecosystem
The Laboratory for Advanced Medicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Laboratory for Advanced Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Laboratory for Advanced Medicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









